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1. Introduction 
Peptides are well known as nitrogen sources to supply various amino acids for many 
different organisms, and also have many hormonal functions in our body. Previous studies 
have reported a secondary role for peptides with specific amino acid sequences that possess 
biological function in vivo (1-8). To prepare biologically active peptides (bioactive peptides), 
food ingredients containing protein are generally hydrolyzed by some proteolytic enzymes. 
In particular, milk proteins such as bovine casein and whey proteins have been used for 
preparations of bioactive peptides because inexpensive and safe sources are readily 
available. Various physiologically functional peptides, such as immunostimulating peptides 
(1), antimicrobial peptides (2), opioid peptides (3), mineral soluble peptides (4) and 
antihypertensive peptides (5-8) and have been isolated from enzymatic hydrolyzates of raw 
food materials and fermented food products.  
Among these bioactive peptides, antihypertensive peptides have been extensively studied 
and reviewed (5-8). Hypertension is a major risk factor in cardiovascular disease, such as 
heart disease and stroke.  In order to reduce the incidence of disease, pharmacological 
substances can be used to decrease high blood pressure to within the normal range. 
Angiotensin I-converting enzyme (kininase II; EC 3.4.15.1) (ACE) is predominantly 
expressed as a membrane-bound ectoenzyme in vascular endothelial cells and several other 
cell types, including absorptive epithelia, neuroepithelia and male germinal cells (9, 10). A 
dipeptidyl carboxypeptidase, ACE catalyzes the production of a vasoconstrictor, 
angiotensin II, and inactivates a vasodilator, bradykinin (11, 12). The first competitive 
inhibitors to ACE were reported as naturally occurring peptides isolated from snake venom 
(13, 14).  Then, inhibitory activities on ACE, which plays an important role in blood pressure 
regulation are generally assessed for preparation of antihypertensive peptides.  
Among lactic acid bacteria, Lactobacillus helveticus had the highest extracellular proteinase 
activity and the highest ability to release the specific antihypertensive peptides in the 
fermented milk (15). So, this paper mainly reviews processing of the antihypertensive 
peptides, Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), by proteolytic enzymes of L. helveticus.   
The antihypertensive effects of these in vitro and in vivo studies, clinical study, and the mode 
of action are also reviewed.  The antihypertensive effect of the L. helveticus fermented milk 
compared to that produced by various lactic acid bacteria and proteolytic systems of L. 
www.intechopen.com
 Biotechnology - Molecular Studies and Novel Applications for Improved Quality of Human Life 160 
helveticus is reviewed for the discussion in more detail. Finally, processing of VPP and IPP 
specific to the L. helveticus is discussed in the context of comparative genome analyses of 
corresponding proteolytic enzymes in various lactic acid bacteria.  
1.1 Antihypertensive peptide in fermented milk 
1.1.1 ACE inhibitory peptides from milk proteins 
Many kinds of ACE inhibitory (ACEI) peptides have been reported from enzymatic 
hydrolyzates of milk protein, as well as synthetic peptides and fermented products (16-24) 
(Table 1). Spontaneously hypertensive rat (SHR) is a useful animal model to evaluate the 
antihypertensive activity of ACEI peptides because the systolic blood pressure of SHR 
reaches over 230 mmHg and is powerful tool for detection of the in vivo effect. Some of the 
orally administered ACEI peptides have demonstrated strong antihypertensive effects in 
SHR (Table 1).  
 
Peptide 
 
Source Preparation 
∗IC50
(µM) 
Dose 
(mg/kg) 
∗∗∗SBP 
(mm Hg) 
<Enzymatic hydrolysate> 
FFVAPFPEVFGK s1-casein Trypsin 77 100 -13.0 
AVPYPQR β-casein Trypsin 15 100 -10.0 
TTMPLW  s1-casein Trypsin 16 100 -13.6 
LKPNM  Aldolase Thermolysin 2.4 60 -23 
LKP  Aldolase Chicken muscle 0.32 60 -18 
IPA  β-lactogloblin Proteinase K 141 8 -31 
VYPFPG  β-casein Proteinase K 221 8 -22 
GKP  β-microglobulin Proteinase K 352 8 -26 
FP  β-casein, albumin Proteinase K 315 8 -27 
YKVPQL  s1-casein Proteinase 22 1 -12.5 
<Fermented products> 
RF  Sake lees Brewing ND 100 -17 
VW  Sake lees Brewing 1.4 100 -10 
YW  Sake lees Brewing 10.5 100 -28 
VY  Sake Brewing 7.1 100 -31 
IYPRY  Sake Brewing 4.1 100 -19 
VPP  β-casein Fermentation 9 1.6 -20 
IPP  β- and κ -casein Fermentation 5 1 -15.1 
YP   s1, β- and κ-casein Fermentation 720 1 -27.4 
ND: Not described 
∗IC50: Peptide concentration that shows 50% inhibition of ACE activity 
∗∗∗SBP: systolic blood pressure of spontaneously hypertensive rat 
Table 1. Antihypertensive peptides derived from caseins by proteolytic action. 
Lactic acid bacteria have proteolytic systems that can hydrolyze milk protein and have been 
reported to utilize the peptides released from the milk protein casein (25-27). Among lactic 
acid bacteria, Lactobacillus helveticus had the highest extracellular proteinase activity and the 
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ability to release the largest amount of peptides in the fermented milk (Table 2). As a result, 
among various kinds of fermented milk, the antihypertensive effect was specific to the L. 
helveticus fermented milk (15). In our study, an antihypertensive effect related to ACEI 
peptides was found in sour milk produced by L. helveticus (19, 28). Two ACE inhibitory 
peptides were purified from sour milk and identified as VPP and IPP. The ACEI activity of the 
two peptides was very high, 9 µM and 5 µM, compared to other reported peptides (Table 1).  
The amino acid sequences of VPP and IPP were found in the primary structure of bovine β-
casein (84-86) (74-76) and κ-casein (108-110), respectively. These peptides were produced 
during fermentation (16), but were not found in the hydrolyzate of casein after digestion with 
an extracellular proteinase of L. helveticus (29). Oral administration of L. helveticus fermented 
milk containing VPP and IPP to SHR, with a single dose of 5 ml/kg body weight, significantly 
decreased systolic blood pressure between 4 and 8 h after administration (28). The 
antihypertensive effect of these two chemically synthesized peptides was also observed 
between 2 and 8 h after administration and the effects were dose-dependent. Furthermore, a 
dose-dependent antihypertensive effect of these two chemically synthesized peptides was also 
observed from 0.1 to 10 mg/kg of body weight (28). 
 
 
Strain 
 
Peptide 
conc. 
Proteinase 
act. 
∗ACEI 
act.
∗∗∗Change in 
SBP 
      (%) (U/ml) (U/ml) (mmHg) 
Non-fermented milk 0.00 - 0 - 5.0 ± 7.3 
(Lactobacilli) 
L. helveticus CP790 0.19 230 58 - 27.4 ± 13.3 ＊＊ 
L. helveticus CP611 0.25 367 70 - 20.0 ± 9.6 ＊＊ 
L. helveticus CP615 0.18 420 51 - 23.0 ± 13.4 ＊＊ 
L. helveticus JCM1006 0.15 182 26 - 15.2 ± 9.3 ＊ 
L. helveticus JCM1120 0.10 112 34 - 6.5± 10.8 
L. helveticus JCM1004 0.21 186 48 - 29.3 ± 13.6 ＊＊ 
L. delbrueckii subsp. bulgaricus CP973 0.19 105 22 - 0.8 ± 8.2 
L. delbrueckii subsp. bulgaricus JCM1002 0.11 124 28 - 4.5 ± 4.0 
L. casei CP680 0.01 35 3 - 0.2 ± 6.6 
L. casei JCM1134 0.00 28 9 - 7.0 ± 11.2 
L. casei JCM1136 0.09 25 18 - 9.6 ± 7.2 
L. acidophilus JCM1132 0.00 28 8 - 8.7 ± 7.8 
L. delbrueckii subsp. lactisJCM1105 0.08 18 16 - 3.3 ± 3.5 
(Streptococci) 
S. thermophilus CP1007 0.02 25 3 - 2.4 ± 8.1 
(Lactococci) 
L. lactis subsp. lactis CP684 0.00 35 4 - 7.3 ± 10.5 
L. lactis subsp. cremoris CP312 0.02 18 4 - 5.8 ± 13.9 
Significant differences from the control, ∗∗p< 0.01, ∗p< 0.05. 
∗ACEI activity: Peptides that show 50% inhibition of ACE activity was defined as one unit. 
∗∗∗SBP: systolic blood pressure of spontaneously hypertensive rat 
Table 2. Antihypertensive effects in spontaneously hypertensive rats and ACE inhibitory 
activities of various fermented milk. 
www.intechopen.com
 Biotechnology - Molecular Studies and Novel Applications for Improved Quality of Human Life 162 
1.2 Clinical effects of the fermented milk  
Hypertension is a major risk factor in cardiovascular diseases, such as heart disease and 
stroke. In order to reduce the incidence of disease, pharmacological substances can be used 
to decrease high blood pressure to within the normal range. In the first Japanese study with 
the fermented milk, hypertensive subjects were randomly assigned to two groups: the one 
group ingested 95 ml of the milk, containing 3.4 mg of VPP and IPP, daily for 8 wk; the 
other group ingested the same amount of artificially acidified milk as a placebo, for 8 wk 
(30). In the fermented milk group, systolic blood pressure decreased significantly between 4 
and 8 wk after the beginning of ingestion, but not in the placebo group (30). Moreover, 
clinical tests were performed for Japanese subjects with different blood pressure levels, 
which confirmed the mild and prolonged effects for the hypertensive subjects following oral 
administration of bioactive milk (30-33) (Fig. 1).  In a pilot study conducted in Finland, the 
antihypertensive effect was also observed in the group ingesting L. helveticus fermented milk 
containing the two tripeptides (34, 35).  Moreover, a recent study indicated significant 
beneficial effects of hypertensive patients ingesting the L. helveticus fermented milk over a 
long period of time for 21 wk (35). There was a significant decrease in systolic blood 
pressure (6.7 ± 3.0 mmHg) by comparative study with placebo group.  
 
Fig. 1. Blood pressure lowering effect of Lactobacillus helveticus fermented milk product for 
subjects with high-normal hypertension  (Nakamura et al., J. Nutritional Food (in Japanese) 
2004, 7, 123-137). Significant difference from initial value (t-test): ∗p <0.05, ∗∗p <0.01. 
Significant difference from placebo group (Bonferroni test): # p<0.05, ## p<0.01.  
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1.3 Processing of antihypertensive peptides in L. helveticus  
1.3.1 Proteolytic system in lactic acid bacteria 
Many kinds of proteolytic enzymes have been reported from lactic acid bacteria, and were 
reviewed extensively (26, 27, 36, 37). The components of the proteolytic systems of lactic 
acid bacteria are divided into three groups, including the extracellular proteinase that 
catalyzes casein breakdown to peptides, peptidases that hydrolyze peptides to amino acids 
and a peptide transport system. The number of proteinases was reported from lactococci, 
which are mainly used in cheese making. The extracellular proteinase activity is linked to 
cell growth in milk and seemed to be essential for utilization of milk protein for growth. The 
gene encoding the proteinases, named prtP, prtH and prtH2, has been sequenced and 
characterized from several of L. lactis strains (38-40).   These proteinases are processed to 
active enzymes by removal of N-terminal polypeptides from the pre-proteinase with the 
help of the maturation protein, PrtM. 
1.4 Processing by a cell wall-associated proteinase 
The first step in casein decomposition is typically caused by an extracellular proteinase, and 
further digestion to amino acids is catalyzed by many kinds of intracellular peptidases (25, 
36). Among the lactic acid bacteria, L. helveticus has the highest extracellular proteinase 
activity and the ability to release the highest amount of peptides in fermented milk (Table 2). 
L. helveticus strains were classified into 2 types based on differences in the extracellular 
proteinase (41). One type has an enzyme with a molecular weight of 170 kDa with homology 
to the lactococcus enzyme, and other has an enzyme with a molecular weight of 45 kDa (29, 
42). Polycloncal antibodies raised against the mature 170 kDa proteinase reacted not only 
with the 170 kDa enzyme but also the 53 kDa protein (Table 3). The 53 kDa protein was 
thought to be a degradation product from the 170 kDa active enzyme. A gene encoding a 
proteinase with a homology to the Lactococcus proteinase was cloned and sequenced from L. 
helveticus CNRZ32 (43). A gene encoding PrtM gene was also cloned from L. helveticus 
CNRZ32. On the other hand, the gene encoding a small type of proteinase with a molecular 
weight of 45 kDa was cloned from L. helveticus CP790 strain (44).  A 46 kDa pre-proteinase 
was activated to the 45 kDa active proteinase by release of 7 amino acids from the N-
terminus with the help of a maturation protein (44, 45).   
Moreover, a slight difference in the specificity of the two types of proteinases toward casein 
was suggested for the two types of L. helveticus strains (46). However, there were no clear 
relationships between proteinase specificity and the antihypertensive effects and the ACEI 
activities of the fermented milk, which depended on the strain of L. helveticus used. The 
extracellular proteinase activity of each L. helveticus strain was almost correlated with ACEI 
activity in the fermented milk (Table 1). These results strongly suggest that the proteolysis of 
casein by the extracellular proteinase is the most important parameter in the processing of 
active components. This possibility is also supported by the fact that the L. helveticus CM4, 
which was selected for its strong proteinase activity compared to other L. helveticus strains, 
has the ability to release ACE inhibitory peptides in the fermented milk (47). The proposed 
importance of the proteinase was also supported by the fact that a proteinase negative 
mutant was not able to generate antihypertensive peptides in the fermented milk, whereas 
the wild-type strain had the ability to release strong antihypertensive peptides in the 
fermented milk (16). Strain CM4, which had the highest antihypertensive peptide 
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No Strain   Subspecies Reactivity (CP790)1 Reactivity (CP53)2 Type 
1 L. helveticus CP39 J3 45 kDa 45 kDa A 
2 L. helveticus CP53 H4 ND5 53, 170 kDa B 
3 L. helveticus CP209 J 45 kDa 45 kDa A 
4 L. helveticus CP210 J 45 kDa 45 kDa A 
5 L. helveticus CP293 J 45 kDa 45 kDa A 
6 L. helveticus CP510 J 45 kDa 45 kDa A 
7 L. helveticus CP611 J 45 kDa 45 kDa A 
8 L. helveticus CP615 J 45 kDa 45 kDa A 
9 L. helveticus CP617 J 45 kDa 45 kDa A 
10 L. helveticus CP789 J 45 kDa 45 kDa A 
11 L. helveticus CP790 J 45 kDa 45 kDa A 
12 L. helveticus JCM1004 H ND 53, 170 kDa B 
13 L. helveticus JCM1006 J 45 kDa 45 kDa A 
14 L. helveticus JCM1007 J ND 53, 170 kDa B 
15 L. helveticus JCM1062 J ND 53, 170 kDa B 
16 L. helveticus JCM1103 H ND 53, 170 kDa B 
17 L. helveticus JCM1120 H ND 53, 170 kDa B 
(Yamamoto et al., 1998, Biosci. Biotech. Biochem. 58, 776-778) 
1Monoclonal antibody to the proteinase from L. helveticus CP790 
2Polyclonal antibody to the proteinase from L. helveticus CP53 
3Classified as L. helveticus biovar jugurti 
4Classified as L. helveticus biovar helveticus 
5Not detected 
Table 3.  Immunological Difference of Proteinases of L. helveticus Strains with Two Types of 
Antibodies. 
production in fermented milk, seemed to have the potential for use as a functional food 
product. Currently, we completed the whole genome sequence of L. helveticus CM4, and the 
results revealed the presence of 2,171 open reading frames in 2,028,493 bp of whole DNA 
sequence (unpublished data). Then, whole genome sequences of CM4 and DPC4571 (48) 
were compared as shown in Table 4 for full understanding of the intracellular processing to 
VPP and IPP (49). As shown in Table 4, three genes for cell-wall associated proteinase genes, 
prtY, prtH2 and prtM2, and 23 kinds of intracellular peptidases were detected in the CM4 
sequence. The genes of prtH2 and prtM2 were detected both in CM4 and DPC4571, but the 
prtM2 was considered to be pseudo-genes for extracellular proteinase in the previous study 
(50). However, no prtH1 and prtM1 genes reported in CNRZ32 (51) were detected in 
sequences in both CM4 and DPC4571 strains. The genes of prtH2 and prtM2 were detected 
both in CM4 and DPC4571, but the prtM2 was considered to be pseudo-genes for 
extracellular proteinase in the previous study. However, no prtH1 and prtM1 genes reported 
in CNRZ32 (51) were detected in sequences in both CM4 and DPC4571 strains. On the other 
hand, one of the cell wall-associated proteinase gene (prtY) corresponding to a 45 kDa 
proteinase previously detected in L. helveticus CP790 strain (41, 42) was detected in CM4 
strain but not in DPC4571 strain (Table 1). These results reveal the cell wall-associated 
extracellular proteinase which plays key role in decomposition of casein might be different 
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among detected proteolytic enzymes between CM4 and DPC4571.  On the other hand,  the 
large size of the proteinase gene (prtH) corresponding to a 200 kDa proteinase and its 
maturation gene (prtM) reported by Pederson et al. (43) were not detected in the CM4 and 
DPC4571 genes. This observation supports our previous results that there are two types of 
extracellular proteinases, and L. helveticus can be classified by the proteinase type as shown 
in Table 4. This result also suggested that the extracellular proteinase might play a key role 
to release high amount of VPP and IPP from the comparative analysis of both proteolytic 
genes (Table 4). 
 
Proteolytic enzyme Gene Molecular weight (kDa) Protein ID Identity 
(%) CM4 DPC4571 DPC4571
Proteinase prtY 47.0 ND - - 
 prtH2 181.6 180.871∗ - 99.2 
 prtM 33.7 32.7 ABX27563 98.0 
Aminopeptidase pepC1 51.4 51.4 ABX26582 98.9 
 pepC2 52.9 50.2 ABX27065 98.6 
 pepN 95.8 95.9 ABX27731 99.4 
 pepN2 57.2 57.2 ABX27544 100.0 
 pepA 41.3 40.1 ABX26758 99.4 
XPDAP pepX 90.5 90.6 ABX27419 99.6 
Endopeptidase pepE 50.0 50.0 ABX26466 99.8 
 pepE2 51.4 50.3 ABX26457 99.8 
 pepF 68.1 68.1 ABX27686 99.3 
 pepO 73.6 73.5 ABX27358 99.4 
 pepO2 73.8 73.5 ABX27211 98.6 
 pepO3 73.1 72.6 ABX26433 99.7 
Tripeptidase pepT 47.1 46.7 ABX27305 99.3 
 pepT2 48.8 48.4 ABX27165 99.5 
Dipeptidase pepD1 54.0 54.1 ABX27625 99.4 
 pepD2 54.9 54.9 ABX27375 99.8 
 pepD3 53.5 53.5 ABX27723 100.0 
 pepV 51.5 51.5 ABX27224 98.9 
 pepDA 53.5 53.5 ABX26492 99.6 
Prolidase pepQ 41.2 41.2 ABX26664 99.5 
 pepQ2 41.4 41.1 ABX27405 99.7 
Prolinase pepPN 35.0 35.0 ABX27633 99.7 
Proline iminopeptidase pepI 33.9 33.8 ABX26375 99.3 
ND: Not detected, *size of the reported pseudo-gene 
Table 4. Genes encoding proteolytic enzymes reported in Lactobacillus helveticus strains 
By the proteolytic action of the extracellular proteinase in CP790 (and CM4), a long β-casein 
peptide with a 28 amino acid residue including VPP and IPP sequences was generated (29) 
(Fig. 2). The proteinase activity is easily repressed by accumulated peptides by the 
proteinase in the fermented milk. Moreover, the enzyme activity is inactivated by pH drop 
during the fermentation. So, the first degradation of casein by the extracellular proteinase 
would be occurred mostly at the beginning of the fermentation.  
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Fig. 2. Postulated proteolytic system for Val-Pro-Pro and Ile-Pro-Pro processing in 
Lactobacillus helveticus. PrtY: cell-wall proteinase, PrtM: maturation protein, PptO: 
oligopeptide transporter, PepO: endopeptidase O, PepO2: endopeptidase O2, PepC2: 
aminopeptidase C2, PepX: X-prolyl dipeptidyl aminopeptidase. Up- and down-regulation 
and amount of release are indicated by arrows as (↑) and (↓), respectively.  
1.4.1 Intracellular processing by some peptidases 
Next, the long peptide was thoroughly hydrolyzed to shorter peptides by intracellular 
peptidases. Intracellular peptidases of L. helveticus and these genes were well reviewed, 
previously (37), however, there was no clear explanation for the processing of VPP and IPP. 
Long peptide containing two kinds of tri-peptide sequences released by the extracellular 
proteinase from β-casein will be incorporated into the cell by the oligopeptide transporter 
(PptO), and processed intracellularly to VPP and IPP by some peptidases (Fig. 2).  Carboxyl 
peptidase most likely needs for the release of C-terminal amino acid from Pro-Pro-X 
sequence. However, recently, a key enzyme that can catalyzed carboxyl terminal processing 
to produce VPP and IPP was detected and purified from the CM4 strain (Fig. 2) (52). The 
enzyme had a homology to an endopeptidase (PepO) from L. helveticus CNRZ32 by amino 
terminal sequence analysis of the purified enzyme (52) and a homology with the deduced 
amino acid sequence of the gene (53). The enzyme can catalyze C-terminal processing of 
VPPFL and IPPLT to VPP and IPP.  
Based on the previous reported characteristics of many peptidases from L. helveticus, 
processing of the N-terminal sequence of VPP and IPP are presumed and summarized in 
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Fig. 2. Generally, amino peptidase shows broad specificity toward amino acid at N-
terminal end, however, amino terminal processing seems to terminate if proline residue is 
present at the N-terminal end in the peptide. However, X-prolyl dipeptidyl 
aminopeptidase (XPDAP) is able to release the di-peptide with a sequence of X-Pro, from 
the N-terminus. On the other hand, aminopeptidase may stop the hydrolysis at a Xaa-Pro-
Pro- sequence if it is present. Therefore, the N-terminal processing to release VPP and IPP 
may be catalyzed by specific aminopeptidases, such as pepC2 and XPDAP as shown in 
Fig. 2. However, for more detailed understanding of these peptide processing in L. 
helveticus, productivities of these peptides in transformant strains expressing the each 
postulated peptidase gene or disrupting of these corresponding peptidase genes from 
wild type strain should be studied.  
1.5 Comparison of the L. helveticus proteolytic system to those in other lactic acid 
bacteria 
The unprocessed proteinase of L. lactis consists of about 1950 amino acid residues, and the 
mature proteinase of L. lactis is a serine type enzyme with a molecular mass between 180-190 
kDa (38-40). The gene encoding the proteinase, named prtP, has been cloned and sequenced 
from several of L. lactis strains (38-40).  These proteinases are processed to active enzymes by 
removal of N-terminal polypeptides from the pre-proteinase with the help of the maturation 
protein, PrtM. Recent decay, whole genome sequences for more than 36 kinds of lactobacilli 
have been reported. The comparative analysis of those genes to other species revealed that 
the CM4 peptidases were more homologous to those in Lactobacillus acidophilus NCFM strain 
(54)(Table 5). Moreover, homologies of CM4 peptidases were detected with peptidases in 
Lactobacillus gasseri ATCC33323 (55) and Lactobacillus johnsonii (NC533) (56). These 
observations suggest that the L. acidophilus group has similar peptidases, endopeptidase, 
XPDAP, and aminopeptidase to L. helveticus CM4 and might have the ability to process VPP 
and IPP if the initial decomposition of casein by an extracellular proteinase is accelerated in 
the fermentation process. 
1.6 Repression of proteolytic systemg  
For growth of lactic acid bacteria in milk, the proteolytic system is activated in the milk 
medium because of a limited amount of amino acids. However, during fermentation in 
the milk medium, the proteolytic system of lactic acid bacteria is repressed by 
accumulated peptides in the fermented milk. The amount of VPP and IPP in the L. 
helveticus fermented milk was also repressed if amino acids were added to the fermented 
milk (57). Microarray analysis of the whole L. helveticus CM4 genome suggested 
extracellular proteinase, endopeptidases, XPDAP, some aminopeptidases and some kinds 
of peptide transporters might be  suppressed by addition of amino acids and be involved 
in the processing of the VPP and IPP (Fig. 2). Regulatory systems (57) that repress the 
proteolytic enzymes and transporters in the presence of amino acids was reported as codY 
system in Lactococcus lactis (58, 59). However, there is no codY-like protein in the 
Lactobacillus genome that has been reported. Thus, a novel type regulatory system for the 
proteolytic system must exist in lactobacilli and strongly affect on the release of VPP and 
IPP in L. helveticus. 
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Lb: Lactobacillus; Lc: Lactococcus 
All values are shown as % homology. Values below 50% were omitted (-). 
Table 5. Proteolytic enzymes in various lactic acid bacteria with homology to enzymes in 
Lactobacillus helveticus CM4, which are expected to have roles in processing Val-Pro-Pro and 
Ile-Pro-Pro 
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2. Conclusion 
In this paper, we showed the potential of bioactive peptides to maintain blood pressure in 
the normal range. About 30% of Japanese people are estimated to be at risk for 
hypertension. Generally, hypertension has been improved by medication and partly by 
controlling the diet. Recently, some food products containing antihypertensive peptides and 
proven antihypertensive effects in clinical studies were recognized as functional foods, 
Foods for Specified Health Use (FOSHU) in Japan. Biologically functional peptides exerting 
a mild influence on hypertensive subjects without adverse effect have enormous potential in 
reducing the risk of cardiovascular disease. 
Among many kinds of commercially available lactic acid bacteria, L. helveticus has ability to 
release functional peptides such as antihypertensive peptides in the fermented milk. These 
potential is strongly depends on the activities of proteolytic enzymes of L. helveticus. So, the 
isolation and mutation breeding of a new L. helveticus strain having strong ability to release 
peptides in the fermented milk is very important to develop industrially useful fermented 
milk. For the understanding of the antihypertensive peptides, based on comparative 
analysis with other Lactobacillus proteolytic enzymes, the extracellular proteinase and 
endopeptidase enzymes seemed to be unique to L. helveticus and seemed at least partially 
explain the L. helveticus specific release of VPP and IPP from fermented milk. For a full 
understanding of protein processing, the genomic information and the analysis of the L. 
helveticus will be a very useful tool and might be needed in future studies. 
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